Inactive Instrument

TBG Diagnostics Limited

Equities

TDL

AU000000TDL4

TBG Diagnostics Limited Announces Exclusive Distribution and Support Partnership with Omixon

November 14, 2016 at 07:56 pm EST

The board of TBG Diagnostics Limited announced an exclusive distribution and support partnership for the Asia Pacific region, including China, Hong Kong, Taiwan and Australia. TBG will be the exclusive distributor of Omixon's Holotype HLA products for HLA typing by NGS. Omixon, domiciled in Cambridge, Massachusetts. TBG chosen by Omixon for distribution of world leading Next Gen Sequencing HLA typing product through Asia Pacific region. Oximon Holotype HLA emerging global leader in HLA typing by NGS. TBG and Oximon are completing a multi-site customer validation program. Partnership to open up new distribution product pipeline for TBG.

Latest news about TBG Diagnostics Limited

TBG Diagnostics Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-08-04	CI
Dongyuan Huaxin Capital Management acquired 5% stake in TBG Inc from TBG Diagnostics Limited.	22-06-06	CI
TBG Diagnostics Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-30	CI
TBG Diagnostics Limited Auditor Raises 'Going Concern' Doubt	22-04-29	CI
Enbridge : EIG Global Energy Partners submits offer for Petrobras pipelines in Brazil, source says	21-08-25	RE
Dongyuan Huaxin Capital Management agreed to acquire 5% stake in TBG Inc from TBG Diagnostics Limited for RMB 5.5 million.	21-06-06	CI
TBG Diagnostics Limited Announces Board Changes	21-03-22	CI
Tbg Diagnostics Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-26	CI
TBG Diagnostics : Posts Over $1 Million Revenue in October-December 2020	21-01-31	MT
TBG Diagnostics' : Unit Gets CE Mark Approval for COVID-19 Antigen Rapid Test	20-11-10	MT
Tbg Diagnostics Limited Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-31	CI
TBG Diagnostics Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-28	CI
Tbg Diagnostics Limited Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-29	CI
TBG Diagnostics Limited acquired an additional 27.9% stake in BioBay Medical Health Ltd.	19-08-29	CI
TBG Diagnostics Limited Announces Resignation of Eugene Cheng as Director	19-05-28	CI
TBG Diagnostics Limited Announces Consolidated Earnings Results for the Year Ended December 31, 2018	19-02-28	CI
TBG Diagnostics Limited Announces Executive Changes	19-02-01	CI
TBG Diagnostics Limited Announces Consolidated Earnings Results for the Half Year Ended June 30, 2018	18-08-30	CI
TBG Diagnostics Limited Approves Election of His-Kai Wang as Director	18-05-27	CI
TBG Diagnostics Limited Announces Board Changes	18-04-25	CI
TBG Diagnostics Limited Reports Unaudited Consolidated Earnings Results for the Year Ended December 31, 2017	18-02-27	CI
TBG Biotechnology Corp to Receive China FDA Approval for High Resolution HLA Genotyping for Hematopietic Cell Transplantation	17-10-22	CI
TBG Diagnostics Limited Announces Consolidated Earnings Results for the Half Year Ended June 30, 2017	17-08-28	CI
TBG Diagnostics Limited, Medigen Corp. and National Taiwan University Hospital Enter Exclusive Licensing Agreement for the Development and Distribution of Patented Product for Evaluation of Adverse Reaction in Antithyroid Drug	17-03-12	CI
TBG Diagnostics Limited Announces Executive Changes	16-12-01	CI

Chart TBG Diagnostics Limited

Duration

Period

More charts

Company Profile

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

Sector

More about the company